SwePub
Sök i LIBRIS databas

  Utökad sökning

(L773:0732 183X OR L773:1527 7755) lar1:(liu)
 

Sökning: (L773:0732 183X OR L773:1527 7755) lar1:(liu) > Randomized phase II...

  • Barlesi, FabriceHop Marseille, AP HP, Marseille, France (författare)

Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer : AVAPERL (MO22089).

  • Artikel/kapitelEngelska2013

Förlag, utgivningsår, omfång ...

  • Alexandria, VA, USA :American Society of Clinical Oncology,2013
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-105275
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-105275URI
  • https://doi.org/10.1200/JCO.2012.42.3749DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • PURPOSE: Maintenance therapy is associated with improved survival in patients with non-small-cell lung cancer (NSCLC), but few studies have compared active agents in this setting. AVAPERL evaluated the safety and efficacy of bevacizumab with or without pemetrexed as continuation maintenance treatment.PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. Those achieving response or stable disease were randomly assigned at a ratio of 1:1 to maintenance bevacizumab 7.5 mg/kg or bevacizumab 7.5 mg/kg plus pemetrexed 500 mg/m(2) once every 3 weeks until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS) after random assignment.RESULTS: In total, 376 patients received induction treatment, 71.9% achieved disease control, and 67.3% were randomly assigned to maintenance therapy, with 125 and 128 receiving single-agent bevacizumab and bevacizumab plus pemetrexed treatment, respectively. At a median follow-up of 8.1 months, PFS from random assignment was significantly improved in the bevacizumab plus pemetrexed arm (median, 3.7 v 7.4 months; hazard ratio, 0.48; 95% CI, 0.35 to 0.66; P < .001) per a stratified model. The PFS benefit extended across age, performance status, smoking history, and induction response (stable disease v partial response) subgroups. Any grade, grade ≥ 3, and serious adverse events occurred more often with bevacizumab plus pemetrexed maintenance. No new safety signals were observed.CONCLUSION: In an unselected population of patients with nonsquamous NSCLC who had achieved disease control with platinum-based chemotherapy plus bevacizumab, bevacizumab plus pemetrexed maintenance was associated with a significant PFS benefit compared with bevacizumab alone. The combination was well tolerated.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Scherpereel, ArnaudUniv Lille, Ctr Hosp Reg, Hop A Calmette, Lille, France (författare)
  • Rittmeyer, AchimLungenfachklin Immenhausen, Immenhausen, Germany (författare)
  • Pazzola, AntonioOsped Civile Santissima, Sassari, Italy (författare)
  • Ferrer Tur, NeusHosp Son Llatzer, Palma De Mallorca, Spain (författare)
  • Kim, Joo-HangYonsei Univ, Coll Med, Seoul 120749, South Korea (författare)
  • Ahn, Myung-JuSungkyunkwan Univ, Sch Med, Seoul, South Korea (författare)
  • Aerts, Joachim G J VAmphia Hosp, Breda, Netherlands (författare)
  • Gorbunova, VeraNN Blokhin Canc Res Ctr Russia, Moscow, Russia (författare)
  • Vikström, AndersÖstergötlands Läns Landsting,Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Lungmedicinska kliniken US(Swepub:liu)andvi77 (författare)
  • Wong, Elaine KF Hoffmann Roche, Basel, Switzerland (författare)
  • Perez-Moreno, PabloF Hoffmann Roche, Basel, Switzerland (författare)
  • Mitchell, LadaF Hoffmann Roche, Basel, Switzerland (författare)
  • Groen, Harry J MUniv Med Ctr Groningen, Groningen, Netherlands (författare)
  • Hop Marseille, AP HP, Marseille, FranceUniv Lille, Ctr Hosp Reg, Hop A Calmette, Lille, France (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Clinical OncologyAlexandria, VA, USA : American Society of Clinical Oncology31:24, s. 3004-30110732-183X1527-7755

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy